Cargando…

Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study)

BACKGROUND: The aim of this study was to evaluate the efficacy and safety of first-line chemotherapy with re-introduction of oxaliplatin (OX) more than 6 months after adjuvant chemotherapy including OX. METHODS: Stage II/III colon cancer patients with neuropathies of grade ≤ 1 who relapsed more than...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ishibashi, Keiichiro, Aoyama, Toru, Kotaka, Masahito, Satake, Hironaga, Tsuji, Yasushi, Kataoka, Masato, Nakamura, Masato, Nagata, Naoki, Sakamoto, Junichi, Oba, Koji, Mishima, Hideyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026470/ https://www.ncbi.nlm.nih.gov/pubmed/33555359 http://dx.doi.org/10.1007/s00280-021-04232-2

Ejemplares similares

First-line chemotherapy with capecitabine/oxaliplatin for advanced gastric cancer: A phase I study
por: Satake, Hironaga, et al.
Publicado: (2017)

Hepatectomy Followed by Adjuvant Chemotherapy with 3‐Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases
por: Satake, Hironaga, et al.
Publicado: (2021)

Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
por: Satake, Hironaga, et al.
Publicado: (2017)

Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)
por: Nakamura, Masato, et al.
Publicado: (2016)

A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy
por: Kotaka, Masahito, et al.
Publicado: (2020)

Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer
por: Munemoto, Yoshinori, et al.
Publicado: (2015)

Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy
por: Kono, Toru, et al.
Publicado: (2013)

Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer: Safety lead‐in results from the QUATTRO-II study
por: Kotani, Daisuke, et al.
Publicado: (2021)

Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial)
por: Kotake, Masanori, et al.
Publicado: (2017)

Association between polymorphisms in EGFR and tumor response during cetuximab and oxaliplatin-based combination therapy in metastatic colorectal cancer: Analysis of data from two clinical trials
por: Maeda, Hiromichi, et al.
Publicado: (2019)

Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients
por: Dai, Xichao, et al.
Publicado: (2016)

Oxaliplatin-Induced Hyperammonemic Encephalopathy in a Patient with Metastatic Pancreatic Cancer: A Case Report
por: Ogata, Takatsugu, et al.
Publicado: (2017)

FOLFIRI Plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study)
por: Mishima, Hideyuki, et al.
Publicado: (2012)

Expressions of 10 genes as candidate predictors of recurrence in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy
por: Kumamoto, Kensuke, et al.
Publicado: (2019)

Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis
por: Matsuda, Chu, et al.
Publicado: (2015)

Phase Ib/II Study of Biweekly TAS‐102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)
por: Satake, Hironaga, et al.
Publicado: (2020)

Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer
por: Ohhara, Yoshihito, et al.
Publicado: (2015)

Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study
por: Soda, Hitoshi, et al.
Publicado: (2015)

Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study
por: Satake, Hironaga, et al.
Publicado: (2018)

Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer—CRAFT study
por: Tezuka, Tohru, et al.
Publicado: (2013)

Oxaliplatin in practice.
por: Misset, J. L.
Publicado: (1998)

A prospective Phase II study to examine the relationship between quality of life and adverse events of first‐line chemotherapy plus cetuximab in patients with KRAS wild‐type unresectable metastatic colorectal cancer: QUACK trial
por: Iwamoto, Shigeyoshi, et al.
Publicado: (2018)

Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial
por: Ooki, Akira, et al.
Publicado: (2020)

Disagreement between patient‐ and physician‐reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial
por: Ooki, Akira, et al.
Publicado: (2020)

Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial
por: Ooki, Akira, et al.
Publicado: (2022)

Comparison of two transarterial chemoembolization regimens in patients with unresectable hepatocellular carcinoma: raltitrexed plus oxaliplatin versus 5-fluorouracil plus oxaliplatin
por: Cui, Wei, et al.
Publicado: (2017)

Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial
por: Yoshino, Takayuki, et al.
Publicado: (2019)

Oxaliplatin related lncRNAs prognostic models predict the prognosis of patients given oxaliplatin-based chemotherapy
por: Zhou, Qing-nan, et al.
Publicado: (2023)

Multicenter phase II study of capecitabine plus oxaliplatin in older patients with advanced gastric cancer: the Tokyo Cooperative Oncology Group (TCOG) GI-1601 study
por: Kawabata, Ryohei, et al.
Publicado: (2023)

Optimal Sequence of Irinotecan and Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer: A Population-Based Observational Study
por: Teng, Chieh-Lin Jerry, et al.
Publicado: (2015)

A severe oxaliplatin immune-induced syndrome after oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC)
por: Ezanno, Anne-Cecile, et al.
Publicado: (2022)

Effect of livergol on the improvement of fatty liver in patients with cancer undergoing irinotecan- and oxaliplatin-based chemotherapy regimen
por: Emami, Hamid, et al.
Publicado: (2018)

Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study
por: Amatu, Alessio, et al.
Publicado: (2022)

The Role of microRNAs in Regulating Cancer Cell Response to Oxaliplatin-Containing Regimens
por: Tavakoli Pirzaman, Ali, et al.
Publicado: (2023)

Oxaliplatin-Based Regimen is Superior to Cisplatin-Based Regimen in Tumour Remission as First-line Chemotherapy for Advanced Gastric Cancer: A Meta-Analysis
por: Zhang, Fei, et al.
Publicado: (2019)

Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane
por: Satake, Hironaga, et al.
Publicado: (2018)

Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan
por: Ogata, Misato, et al.
Publicado: (2020)

FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study(†)
por: Iwamoto, S., et al.
Publicado: (2015)

Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk
por: Shimokawa, Mototsugu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hg46tkeduljtsvts4un634bka2